Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Wray, Justin ^a   Williamson, Elizabeth A ^a   Royce, Melanie ^a   Shaheen, Montaser ^a   Beck, Brian D ^b   Lee, Suk Hee ^b   Nickoloff, Jac A ^c,d   Hromas, Robert ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GYRASE INHIBITOR; PROTEIN METNASE; TRANSPOSASE; UNCLASSIFIED DRUG; ANTHRACYCLINE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; ENZYME INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; SETMAR PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; METAPHASE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; BREAST TUMOR; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; METABOLISM; TUMOR CELL LINE;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS;

EID: 65449139882     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005323     Document Type: Article

References (24)

1. Garces CA, Cance WG (2004) Neoadjuvant chemotherapy of breast cancer. The American Surgeon 70: 565-569.
2. Baldwin EL, Osheroff N (2005) Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5: 363-372.
3. Damelin M, Bestor TH (2007) The decatenation checkpoint. British Journal of Cancer 96: 201-205.
4. Clarke DJ, Gimenez-Abian JF (2000) Checkpoints controlling mitosis. Bioessays 22: 351-363.
5. Clarke DJ, Vas AC, Andrews CA, Diaz-Martinez LA, Gimenez-Abian JF (2006) Topoisomerase II checkpoints: universal mechanisms that regulate mitosis. Cell Cycle 5: 1925-1928.
6. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nature Reviews 3: 430-440.
7. Downes CS, Clarke DJ, Mullinger AM, Gimenez-Abian JF, Creighton AM, Johnson RT (1994) A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372: 467-470.
8. Mikhailov A, Shinohara M, Rieder CL (2004) Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol 166: 517-526.
9. Skoufias DA, Lacroix FB, Andreassen PR, Wilson L, Margolis RL (2004) Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Molecular Cell 15: 977-990.
10. Toyoda Y, Yanagida M (2006) Coordinated requirements of human topo II and cohesin for metaphase centromere alignment under Mad2-dependent spindle checkpoint surveillance. Molecular Biology of the Cell 17: 2287-2302.
11. Deming PB, Cistulli CA, Zhao H, Graves PR, Piwnica-Worms H, et al. (2001) The human decatenation checkpoint. Proc Natl Acad Sci U S A 98: 12044-12049.
12. Deming PB, Flores KG, Downes CS, Paules RS, Kaufmann WK (2002) ATR enforces the topoisomerase II-dependent G2 checkpoint through inhibition of Plk1 kinase. J Biol Chem 277: 36832-36838.
13. Nakagawa T, Hayashita Y, Maeno K, Masuda A, Sugito N, et al. (2004) Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines. Cancer Res 64: 4826-4832.
14. Doherty SC, McKeown SR, McKelvey-Martin V, Downes CS, Atala A, et al. (2003) Cell cycle checkpoint function in bladder cancer. Journal of the National Cancer Institute 95: 1859-1868.
15. Lee SH, Oshige M, Durant ST, Rasila KK, Williamson EA, et al. (2005) The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci U S A 102: 18075-18080.
16. Hromas R, Wray J, Lee SH, Martinez L, Farrington J, et al. (2008) The human set and transposase domain protein Metnase interacts with DNA Ligase IV and enhances the efficiency and accuracy of non-homologous end-joining. DNA Repair (Amst) 7: 1927-1937.
17. Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, et al. (2008) Human Pso4 is a Metnase (SETMAR)-binding partner that regulates Metnase function in DNA repair. J Biol Chem 283: 9023-9030.
18. Williamson EA, Farrington J, Martinez L, Ness S, O'Rourke J, et al. (2008) Expression levels of the human DNA repair protein metnase influence lentiviral genomic integration. Biochimie 90: 1422-1426.
19. Williamson EA, Rasila KK, Corwin LK, Wray J, Beck BD, et al. (2008) The SET and transposase domain protein Metnase enhances chromosome decatenation: regulation by automethylation. Nucleic Acids Res 36: 5822-5831.
20. Richardson DS, Johnson SA (1997) Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood reviews 11: 201-223.
21. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, et al. (2001) Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 1: 113-130.
22. Felix CA (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Medical and Pediatric Oncology 36: 525-535.
23. Ishida R, Miki T, Narita T, Yui R, Sato M, et al. (1991) Inhibition of intracellular topoisomerase II by antitumor bis(2, 6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 4909-4916.
24. Roman Y, Oshige M, Lee Y-J, Goodwin K, Georgiadis MM, et al. (2007) Biochemical characterization of a SET and transposase fusion protein, Metnase (SETMAR) for its DNA binding and DNA cleavage activity. Biochemistry 46: 11369-11376.